F-Prime Capital
Venture capital firm affiliated with Fidelity Investments, with dedicated healthcare and technology practices. One of the longest-standing life sciences investors with deep expertise in therapeutics, diagnostics, and healthcare technology.
Location
Cambridge, USA
Founded
1969
AUM
$3B+
Investment Range
$5M - $50M
Portfolio Companies
2
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c
Investment Thesis
F-Prime Capital invests at the intersection of healthcare and technology, backing companies that can transform patient care through innovative therapeutics, diagnostics, and digital health solutions. They leverage their long history and Fidelity relationship to support companies from seed through public markets.
Team
Partners / Managing Directors (Health & Bio Focus)
- David Schenkein, MD - General Partner, Healthcare
- Chen Yu - General Partner, Healthcare
- Stacie Weninger, PhD - General Partner, Healthcare
- John Lin, MD - General Partner, Healthcare
Other Key Team Members
- Todd Dagres - General Partner, Technology
Focus Areas
- Therapeutics
- Diagnostics
- Digital Health
- Healthcare Technology
- Life Science Tools
- Mental Health
- Gene Therapy
Notable Exits
- Moderna - Early investor in mRNA pioneer (NASDAQ: MRNA)
- SonderMind - Mental health platform (growth)
- Prime Medicine - Gene editing therapeutics
- Multiple successful biotech IPOs
Sources
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| Prime Medicine | Cambridge, Massachusetts, USA | 2019 | biotechgene-editing+2 |
| SonderMind | Denver, Colorado, USA | 2017 | digital-healthmental-health+3 |